Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1996 5
1997 9
1998 4
1999 4
2000 12
2001 36
2002 61
2003 94
2004 106
2005 193
2006 193
2007 249
2008 269
2009 298
2010 368
2011 453
2012 435
2013 423
2014 390
2015 374
2016 355
2017 360
2018 337
2019 344
2020 360
2021 371
2022 334
2023 323
2024 313
2025 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,176 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Hypercalcemia of Malignancy.
Chakhtoura M, El-Hajj Fuleihan G. Chakhtoura M, et al. Endocrinol Metab Clin North Am. 2021 Dec;50(4):781-792. doi: 10.1016/j.ecl.2021.08.002. Endocrinol Metab Clin North Am. 2021. PMID: 34774248 Review.
The treatment of hypercalcemia of malignancy (HCM) consists of enhancing renal calcium excretion, mostly through hydration with isotonic fluids and the use of antiresorptive therapies. Intravenous zoledronic acid is currently the first-line treatment. Subcutaneous d …
The treatment of hypercalcemia of malignancy (HCM) consists of enhancing renal calcium excretion, mostly through hydration with isotonic flu …
Differences between zoledronic acid and denosumab for breast cancer treatment.
Ishikawa T. Ishikawa T. J Bone Miner Metab. 2023 May;41(3):301-306. doi: 10.1007/s00774-023-01408-z. Epub 2023 Mar 7. J Bone Miner Metab. 2023. PMID: 36879056 Review.
Zoledronic acid and denosumab are bone-modifying agents that are clinically important in multiple aspects of bone management for breast cancer patients. ...Zoledronic acid is the most potent bisphosphonate. It provides significant benefits for improvin …
Zoledronic acid and denosumab are bone-modifying agents that are clinically important in multiple aspects of bone management f …
Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J, Lin X, Sun L, Zhang Q, Jiang Y, Wang O, Xing X, Xia W, Li M. Liu J, et al. J Clin Endocrinol Metab. 2024 Jun 17;109(7):1827-1836. doi: 10.1210/clinem/dgad732. J Clin Endocrinol Metab. 2024. PMID: 38198649 Free PMC article. Clinical Trial.
OBJECTIVE: We aimed to investigate the effects of denosumab on bone mineral density (BMD), spinal morphometry, and safety in children with OI compared with zoledronic acid. METHODS: In this prospective study, 84 children or adolescents with OI were randomized to rec …
OBJECTIVE: We aimed to investigate the effects of denosumab on bone mineral density (BMD), spinal morphometry, and safety in children with O …
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA, MacDonald R, Forte ML, Rosebush CE, Ensrud KE, Schousboe JT, Nelson VA, Ullman K, Butler M, Olson CM, Taylor BC, Brasure M, Wilt TJ. Fink HA, et al. Ann Intern Med. 2019 Jul 2;171(1):37-50. doi: 10.7326/M19-0533. Epub 2019 Apr 23. Ann Intern Med. 2019. PMID: 31009947 Free article.
In women with osteopenia or osteoporosis, 6 years of zoledronic acid reduced clinical fractures (HR, 0.73 [CI, 0.60 to 0.90]), including nonvertebral fractures (high SOE) and clinical vertebral fractures (moderate SOE). ...After 3 to 5 years of treatment, bisphospho …
In women with osteopenia or osteoporosis, 6 years of zoledronic acid reduced clinical fractures (HR, 0.73 [CI, 0.60 to 0.90]), …
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer.
Frieling JS, Tordesillas L, Bustos XE, Ramello MC, Bishop RT, Cianne JE, Snedal SA, Li T, Lo CH, de la Iglesia J, Roselli E, Benzaïd I, Wang X, Kim Y, Lynch CC, Abate-Daga D. Frieling JS, et al. Sci Adv. 2023 May 3;9(18):eadf0108. doi: 10.1126/sciadv.adf0108. Epub 2023 May 3. Sci Adv. 2023. PMID: 37134157 Free PMC article.
Bisphosphonates and lifespan.
Center JR, Lyles KW, Bliuc D. Center JR, et al. Bone. 2020 Dec;141:115566. doi: 10.1016/j.bone.2020.115566. Epub 2020 Jul 31. Bone. 2020. PMID: 32745686 Review.
Zoledronate.
Reid IR, Green JR, Lyles KW, Reid DM, Trechsel U, Hosking DJ, Black DM, Cummings SR, Russell RGG, Eriksen EF. Reid IR, et al. Bone. 2020 Aug;137:115390. doi: 10.1016/j.bone.2020.115390. Epub 2020 Apr 27. Bone. 2020. PMID: 32353565
Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.
Ouyang Z, Li H, Zhai Z, Xu J, Dass CR, Qin A, Dai K. Ouyang Z, et al. Curr Drug Targets. 2018;19(5):409-421. doi: 10.2174/1573399811666150615145409. Curr Drug Targets. 2018. PMID: 26073860 Review.
OBJECTIVE: The present review summarizes the controversial effects of zoledronic acid on primary tumor burden and pulmonary metastases in osteosarcoma. We also analyze the clinical effectiveness of zoledronic acid alone and in combination with chemothe …
OBJECTIVE: The present review summarizes the controversial effects of zoledronic acid on primary tumor burden and pulmonary me …
Authors' Reply.
Marques IDB, Elias RM, Moysés RMA, David-Neto E. Marques IDB, et al. J Am Soc Nephrol. 2019 May;30(5):906. doi: 10.1681/ASN.2019020124. Epub 2019 Mar 25. J Am Soc Nephrol. 2019. PMID: 30910936 Free PMC article. No abstract available.
6,176 results